nonhistone domain macroH2A as PARP inhibitor-1 activity, and use thereof

Inhibitor (adenosine 5'-diphospho-ribose) polymerase nucleic enzyme poly [ "poly (ADP-ribose) polymerase 1 (PARP-1)"] for use as a medicament in the prevention or treatment of a disease associated with activation PARP-1 selected from the group consisting of tissue damage resulting from cell damage or death due to necrosis or apoptosis, damage neural tissue resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases, vascular stroke, cardiovascular disorders, degeneration macular age related, AIDS, immune diseases related to age, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, immune diseases related to age, inflammatory disorders, dystrophy muscular, osteoarthritis, osteoporosis, acute and / or chronic renal failure, retinal ischemia, shock s epticemico, skin aging, wherein said inhibitor has a phosphoesterase activity and comprises an amino acid sequence of nonhistone C-terminal domain of a selected macroH2A histone the group consisting of non-histone C-terminal domain of human macroH2A1.1 (amino acids 121-369 of SEQ ID NO: 1), macroH2A1.2 (amino acids 120-371 of SEQ ID NO: 2), and macroH2A2 (amino acids 121-372 of SEQ ID NO: 3) histone.